For solid tumors, a CAR specific for both HER2 and MUC1 had promising in vitro results in a breast cancer model, and a dual-target CAR specific for HER2 and IL13Rα2 showed greater success than single-target CARs in a xenograft glioma model (86, 87). Here, IL13RA2 is linked to central nervous system cancer.